This double-blind, placebo-controlled, 4-period crossover study (n≈32) compared single doses of LSD 100 µg, psilocybin 20 mg, mescaline 300/500 mg and placebo in healthy volunteers to characterise acute subjective, physiological and neural effects.
The LPM study is a double-blind, placebo-controlled, four-period crossover in healthy volunteers comparing single oral doses of LSD (100 µg), psilocybin (20 mg), mescaline (300 or 500 mg) and placebo to determine whether these serotonergic hallucinogens produce qualitatively similar subjective alterations and brain activity patterns.
Outcomes include validated psychometric measures of subjective experience, physiological monitoring, and magnetic resonance imaging to investigate psychological, physiological and neuronal variables associated with acute psychedelic effects.
Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
100 µg (0.1 mg)
Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
300 or 500 mg
Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
Mannitol